Background: Beta-lactam antibiotic-related liver enzyme derangement can limit treatment options for infective exacerbations in cystic fibrosis (CF) bronchiectasis. Aim: To identify risk factors for elevated liver function tests (LFT) in CF patients receiving parenteral antibiotics. Methods: All patients attending The Prince Charles Hospital (TPCH) Adult CF Centre in 2012 were identified using the CF Research Database and CF Data Registry. Biochemistry and haematology panels between 1 January 2012 and 31 December 2012 for each patient were retrieved from Queensland Health Pathology and private pathology providers. Patients with LFT more than three times the upper limit of normal were identified. For each laboratory test, concurrently adminis...
Previous reports of lung function in cystic fibrosis (CF) patients with liver disease have shown wor...
Liver involvement in Cystic Fibrosis (CF) is much less frequent than both pulmonary and pancreatic d...
Hepatopulmonary syndrome (HPS) is a liver-induced lung disorder defined as a triad of liver disease,...
Background:Identification of patients at risk for developing cirrhotic cystic fibrosis liver disease...
Aims In clinical trials, elevated liver transaminase levels in patients taking lumacaftor/ivacaftor...
In clinical trials, elevated liver transaminase levels in patients taking lumacaftor/ivacaftor thera...
International audienceCystic fibrosis (CF)-related liver disease (CFLD) is a common symptom in patie...
Changes in the liver and bile ducts observed in patients diagnosed with cystic fibrosis result from ...
Liver disease associated with cystic fibrosis has been increasingly diagnosed during recent years pr...
AbstractBackgroundClinical trials in cystic fibrosis (CF) currently use laboratory-specific referenc...
Context: A subset ( 483%-5%) of patients with cystic fibrosis (CF) develops severe liver disease wit...
Incidence of liver disease (LD) associated with cystic fibrosis (CF) and its clinical characterizati...
Cystic fibrosis-associated liver disease (CFLD) affects ca. 30 % of patients. The CFLD is now consid...
AbstractBackgroundHypersensitivity reactions to parenterally administered antibiotics (HRPA) are a s...
Background: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, ...
Previous reports of lung function in cystic fibrosis (CF) patients with liver disease have shown wor...
Liver involvement in Cystic Fibrosis (CF) is much less frequent than both pulmonary and pancreatic d...
Hepatopulmonary syndrome (HPS) is a liver-induced lung disorder defined as a triad of liver disease,...
Background:Identification of patients at risk for developing cirrhotic cystic fibrosis liver disease...
Aims In clinical trials, elevated liver transaminase levels in patients taking lumacaftor/ivacaftor...
In clinical trials, elevated liver transaminase levels in patients taking lumacaftor/ivacaftor thera...
International audienceCystic fibrosis (CF)-related liver disease (CFLD) is a common symptom in patie...
Changes in the liver and bile ducts observed in patients diagnosed with cystic fibrosis result from ...
Liver disease associated with cystic fibrosis has been increasingly diagnosed during recent years pr...
AbstractBackgroundClinical trials in cystic fibrosis (CF) currently use laboratory-specific referenc...
Context: A subset ( 483%-5%) of patients with cystic fibrosis (CF) develops severe liver disease wit...
Incidence of liver disease (LD) associated with cystic fibrosis (CF) and its clinical characterizati...
Cystic fibrosis-associated liver disease (CFLD) affects ca. 30 % of patients. The CFLD is now consid...
AbstractBackgroundHypersensitivity reactions to parenterally administered antibiotics (HRPA) are a s...
Background: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, ...
Previous reports of lung function in cystic fibrosis (CF) patients with liver disease have shown wor...
Liver involvement in Cystic Fibrosis (CF) is much less frequent than both pulmonary and pancreatic d...
Hepatopulmonary syndrome (HPS) is a liver-induced lung disorder defined as a triad of liver disease,...